Fmr Llc - Apr 17, 2024 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role
Other*
Signature
Bryan Comtois, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
GPCR
Transactions as of
Apr 17, 2024
Transactions value $
$0
Form type
4
Date filed
4/19/2024, 02:13 PM
Previous filing
Nov 21, 2024
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GPCR Ordinary Shares 45.1K Apr 17, 2024 F-Prime Capital Partners Life Sciences Advisors Fund VI LP
holding GPCR Ordinary Shares 531K Apr 17, 2024 F-Prime Capital Partners Life Sciences Fund VI LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GPCR American Depositary Shares 1.54M Apr 17, 2024 Ordinary Shares 4.63M Shares held by persons and entities whose shares are subject to reporting by the undersigned F1
holding GPCR American Depositary Shares 41 Apr 17, 2024 Ordinary Shares 123 FIMM, LLC F1
holding GPCR American Depositary Shares 2.73K Apr 17, 2024 Ordinary Shares 8.2K F-Prime Capital Partners Life Sciences Advisors Fund VI LP F1
holding GPCR American Depositary Shares 32.2K Apr 17, 2024 Ordinary Shares 96.5K F-Prime Capital Partners Life Sciences Fund VI LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Fmr Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC.